India Drug Approvals — July 28, 2026
The sole filing in this session is a USFDA final approval for Alembic Pharmaceuticals' Prucalopride Tablets, a generic version of Motegrity for chronic idiopathic constipation. With an estimated US market size of $100 million, this approval adds to Alembic's strong track record of 245 cumulative ANDA approvals. The event is moderately material (6/10) and sentiment is positive, but the lack of period-over-period comparisons, insider activity, or forward-looking guidance limits the depth of synthesis. The quiet session underscores a sector-wide lull in major drug approval news from Indian pharma companies, with no other filings to compare or contrast. Investors should monitor Alembic's upcoming earnings calls and any additional pipeline updates for further catalysts.